| Dosing (Adults):
Influenza A treatment: Oral: 100 mg twice daily; initiate within 24-48 hours after onset of symptoms; discontinue as soon as possible based on clinical response (generally within 3-5 days or within 24-48 hours after symptoms disappear).
Influenza A prophylaxis: Oral: 100 mg twice daily; continue treatment throughout the peak influenza activity in the community or throughout the entire influenza season in patients who cannot be vaccinated. Development of immunity following vaccination takes ~2 weeks; amantadine therapy should be considered for high-risk patients from the time of vaccination until immunity has developed.
Drug-induced extrapyramidal symptoms: Oral: 100 mg twice daily; may increase to 300-400 mg/day, if needed.
Parkinson's disease: Oral: 100 mg twice daily as sole therapy; may increase
Elderly: Influenza A prophylaxis or treatment: 100 mg/day in patients over 65 years.
Supplied: 100 mg capsule / tablet. Syrup: 50 mg/5 ml.
TAMIFLU is an influenza neuraminidase inhibitor indicated for:
Important Limitations of Use:
Treatment of Influenza
Table 2 Recommended Dose Adjustments for Treatment of Influenza in Adult Patients with Renal Impairment or End Stage Renal Disease (ESRD) on Dialysis
Prophylaxis of Influenza
Table 3 Recommended Dose Adjustments for Prophylaxis of Influenza in Adult Patients with Renal Impairment or End Stage Renal Disease (ESRD) on Dialysis
| Drug UPDATES: RAPIVAB™ (peramivir injection), for intravenous use
[Drug information / PDF]
Dosing: Click (+) next to Dosage and Administration section (drug info link)
Initial U.S. Approval: 2014
Mechanism of Action: Peramivir is an antiviral drug with activity against influenza virus
INDICATIONS AND USAGE:
Limitations of Use:
HOW SUPPLIED:: Each vial of RAPIVAB injection contains 200 mg per 20 mL (10 mg per mL) as a clear, colorless solution
| INDICATIONS: Rimantadine HCl is indicated for the prophylaxis and treatment of illness caused by various strains of influenza A virus in adults.
Dosing (Adults): The recommended adult dose of rimantadine HCl is 100 mg twice a day. In patients with severe hepatic dysfunction, renal failure (CrCl ≤ 10 ml/min) and elderly nursing home patients, a dose reduction to 100 mg daily is recommended. There are currently no data available regarding the safety of rimantadine during multiple dosing in subjects with renal or hepatic impairment. Because of the potential for accumulation of rimantadine metabolites during multiple dosing, patients with any degree of renal insufficiency should be monitored for adverse effect, with dosage adjustments being made as necessary. Rimantadine HCl therapy should be initiated as soon as possible, preferably within 48 hours after onset of signs and symptoms of influenza A infection. Therapy should be continued for approximately seven days from the initial onset of symptoms.
Treatment of Influenza: RELENZA is indicated for treatment of uncomplicated acute illness due to influenza A and B virus in adults and pediatric patients 7 years of age and older who have been symptomatic for no more than 2 days.
Prophylaxis of Influenza: RELENZA is indicated in adults and pediatric patients 5 years of age and older for prophylaxis of influenza.
Community Outbreaks: The recommended dose of RELENZA for prophylaxis of influenza in adults and adolescents in a community setting is 10 mg once daily for 28 days. The 10-mg dose is provided by 2 inhalations (one 5-mg blister per inhalation). The dose should be administered at approximately the same time each day. There are no data on the effectiveness of prophylaxis with RELENZA in a community outbreak when initiated more than 5 days after the outbreak was identified in the community. The safety and effectiveness of prophylaxis with RELENZA have not been evaluated for longer than 28 days duration.
National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user’s use of or reliance upon this material.PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read the disclaimer